Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2014 · 10-Q
Revenue$3.07M$3.07M+31.7% vs Q1 2013 Net Income-$1.85M-$1.85MN/M vs Q1 2013 EPS Diluted-$0.05-$0.05N/M vs Q1 2013 Gross Profit$985,008+46.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow-$1,404,785N/M Free Cash Flowderived-$1,419,408N/M Margins · derivedGross margin32.0%+3.2 pt vs Q1 2013
Operating margin-59.8%+0.9 pt vs Q1 2013
Net margin-60.1%+0.9 pt vs Q1 2013
ended Mar 29, 2014 · filed May 8, 2014 · 40 d after period end